The Effectiveness of Preoperative Trimetazidine on Myocardial Preservation in Coronary Artery Bypass Graft Patients: A Systematic Review and Meta-Analysis

Nan Zhang\(^a\)  Jiayan Lei\(^c\)  Qing Liu\(^b\)  Wei Huang\(^a\)  Hua Xiao\(^a\)  Han Lei\(^a\)

\(^a\)Department of Cardiology and \(^b\)Center for Clinical Research, The First Affiliated Hospital of Chongqing Medical University, and \(^c\)The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Key Words
Coronary artery bypass graft · Trimetazidine · Myocardial preservation · Myocardium

Abstract
Background: Coronary artery bypass grafting (CABG) is a key and effective surgical treatment modality for coronary artery disease. Unfortunately, ischemia-reperfusion injury during and after CABG can lead to reversible and irreversible myocardial damage. Trimetazidine [1-(2,3,4-trimethoxybenzyl)piperazine dihydrochloride] is a metabolic anti-ischemic agent with demonstrated cardioprotective effects; however, its effects with respect to myocardial preservation in CABG patients remain unclear. Methods: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to investigate the effectiveness of myocardial preservation of preoperative trimetazidine therapy in CABG patients by assessing the postoperative levels of several blood-based biochemical markers of myocardial injury, including creatine kinase (CK), creatine kinase-muscle and brain (CK-MB), creatine phosphokinase (CPK), troponin T (TnT) and troponin I (TnI). The RCTs were classified into two subgroup analyses by the timing of sample collection (either ≤12 or >12 h after CABG). Results: Six RCTs were finally included in the meta-analysis. The pooled effect sizes showed significantly lower postoperative levels of CK, CK-MB, TnT and TnI in the trimetazidine-treated CABG patients relative to control CABG patients. However, there were no significant differences in the postoperative CPK levels between trimetazidine-treated CABG patients relative to control CABG patients. In both the ≤12 and >12 h post-CABG subgroup analyses, significant differences in CK, CK-MB, TnT and TnI were detected between the trimetazidine-treated CABG patients relative to control CABG patients. Conclusions: Preoperative trimetazidine therapy appears to have a positive effect on myocardial preservation in CABG patients.

© 2015 S. Karger AG, Basel

Introduction

Coronary artery bypass grafting (CABG) is a key and effective surgical treatment modality for coronary artery disease [1]. Unfortunately, ischemia-reperfusion injury during and after CABG can lead to reversible and irreversible myocardial damage [2]. Clinically, ischemia-reperfusion injury after CABG can manifest as myocardial...
stunning, perioperative myocardial infarction, low cardiac output or arrhythmia. In patients dying soon after CABG, histopathological evidence of ischemia-reperfusion is detected in 25–45% postmortem [3, 4]. Furthermore, biochemical evidence of myocardial injury (e.g. elevated levels of circulating creatine kinase-muscle and brain, CK-MB, and/or troponin) has been clearly linked with adverse events after CABG [5]. Therefore, myocardial preservation is a key issue for patients undergoing CABG.

Trimetazidine [1-(2,3,4-trimethoxybenzyl)piperazine dihydrochloride] is a metabolic anti-ischecmic agent with demonstrated cardioprotective effects that does not alter cardiac hemodynamics [6]. Accordingly, meta-analyses of randomized controlled trials (RCTs) have validated the beneficial cardioprotective effects of trimetazidine therapy in patients with stable angina pectoris and congestive heart failure (CHF) [7–11]. Although trimetazidine shows promise as an anti-ischemic agent, its effects with respect to myocardial preservation in CABG patients remain unclear.

Therefore, here we conducted a systematic review and meta-analysis of RCTs to investigate the effectiveness of myocardial preservation of pre-operative trimetazidine therapy in CABG patients by assessing the postoperative levels of several blood-based biochemical markers of myocardial injury, including creatine kinase (CK), CK-MB, creatine phosphokinase (CPK), troponin T (TnT) and troponin I (TnI) [12].

Methods

This study was performed in accordance with the PRISMA recommendations for systematic reviews and meta-analyses [13] and the Cochrane handbook for systematic reviews of interventions [14]. The protocol of this study has not been published.

Search Strategy

We performed a systematic search for RCTs investigating the use of preoperative trimetazidine in CABG patients through the following databases: MEDLINE, PubMed, Web of Science and China National Knowledge Infrastructure with the following key words and MeSH headings: ‘coronary artery bypass graft’ OR ‘CABG’ OR ‘coronary bypass surgery’) AND (‘trimetazidine’ OR ‘vastarel’ OR ‘vasorel’) AND (‘randomized controlled trial’ OR ‘RCT’). The time period was restricted from January 1, 1971, to December 31, 2013, and the languages were restricted to English and Chinese. In addition, all references of the related reviews and articles were searched to find additional studies.

Study Selection

References were evaluated by two individual investigators (N.Z., W.H.) using the following predefined inclusion and exclusion criteria.

Inclusion Criteria

RCTs conducted in CABG patients treated with trimetazidine (i.e. RCTs directly comparing trimetazidine and placebo in CABG patients) regardless of sample size.

Exclusion Criteria

(i) Failure to report a relevant data outcome (i.e. postoperative circulating levels of CK, CK-MB, CPK, TnT or TnI) and (ii) reviews, editorials, comments or reports from scientific sessions or discussions.

Decision for inclusion was made on consensus. Any conflict between the reviewers was resolved by an author group discussion, after which the primary authors made the final decision. Evaluation was based on title and abstract whenever available. Full-text articles from potentially relevant references were obtained in electronic or printed format and re-evaluated for inclusion by the same investigators as before. The PICOS (patients, interventions, comparators, outcomes and settings) method was used to assess whether the references fully complied with the inclusion and exclusion criteria [15]. As a full-text article was required for this systematic review and meta-analysis, references whose full texts we could not acquire either electronically or as printed copies from our medical library were excluded. Multiple reports from a single study were considered as one study.

Bias Evaluation

As instructed in the Cochrane handbook for systematic reviews of interventions [14], the investigators performed an evaluation of bias rather than of methodological quality. Studies included were evaluated for bias using methods described in the Cochrane handbook. The following 6 dimensions were considered in the bias assessment tool: allocation sequence generation, allocation concealment, blinding of participants, incomplete outcome data, selective outcome reporting, and other sources of bias. Evaluation was done by two independent assessors (N.Z., W.H.) to improve the validity. In addition, publication bias was assessed by visual inspection of funnel plots.

Data Extraction

Data on key characteristics of the RCTs were extracted by two independent researchers (N.Z., W.H.), including country, sample size, age, preoperative trimetazidine course of therapy (duration and routes), measured outcomes (postoperative circulating levels of CK, CK-MB, CPK, TnT and TnI) and the postoperative follow-up period (mean hours), using an Excel data extraction form. Any conflict between the reviewers was solved by a group discussion, after which the primary authors made the final decision.

Meta-Analyses

Data were entered into Review Manager 5.0 software to conduct the heterogeneity analysis and meta-analysis (Review Manager, version 5 for Windows, 2008). We analyzed myocardial preservation in CABG patients based on their postoperative levels of CK, CK-MB, CPK, TnT and TnI. Since continuous data from different scales were extracted, the standardized mean difference (SMD) was calculated for effect size based on sample size and 95% confidence intervals (CIs) for each study, and for the pooled studies using variance analysis [16]. A 2-sided p value of less than 0.05 was deemed significant for all analyses.
The fixed effect model was used to pool data if there was no heterogeneity detected; otherwise, the random effects model was used. $I^2$ was the percentage of variation attributed to heterogeneity with an $I^2$ statistic of 25–50% considered low, 50–75% considered moderate and ≥75% considered high. Heterogeneity was considered significant for p values of Cochrane’s Q statistic of less than 0.10 and $I^2$ values of greater 50% [17, 18]. If heterogeneity was detected, we conducted a sensitivity analysis to verify the reliability of the meta-analysis results by excluding certain studies and then recalculating the pooled estimates for the remaining studies.

**Results**

The flowchart of study selection is provided in figure 1. The initial literature search yielded 82 records, of which 6 RCTs remained after removal of duplicate records and application of all inclusion and exclusion criteria [19–24]. In the following subgroup meta-analysis based on each of the postoperative myocardial injury markers (i.e. CK, CK-MB, CPK, TnT and TnI), these 6 RCTs were classified into 2 subgroups by the timing of sample collection (either ≤12 or >12 h after CABG).

**Meta-Analysis: Postoperative CK**

Figure 2 shows a Forest plot evaluating preoperative trimetazidine therapy by postoperative circulating CK levels. With respect to postoperative circulating CK levels, Iskesen et al. [22] and Vedrinne et al. [21] each reported 3 data outcomes. There was high heterogeneity ($I^2 = 99\%$, $p < 0.00001$); thus, the random effects model was used.

The pooled effect size showed significant differences in postoperative CK levels (SMD = −138.99, 95% CI = −219.83 to −58.16, $p = 0.0008$) between the trimetazidine and control groups. In the ≤12 h postoperation subgroup analysis, all RCTs with the exception of Iskesen et al. [22], subgroups A and B, showed significant differences in postoperative CK levels between the trimetazidine and control groups. In the >12 h postoperation subgroup analysis, the 2 RCTs showed significant differences in postoperative CK levels between the trimetazidine and control groups.

**Meta-Analysis: Postoperative CK-MB**

Figure 3 shows a Forest plot evaluating pre-operative trimetazidine therapy by post-operative circulating CK-MB levels. With respect to postoperative circulating CK-MB levels, Iskesen et al. [22] reported 2 data outcomes, Sher-i-Murtaza et al. [19] reported 3 data outcomes, Tünerir et al. [20] reported 4 data outcomes, Vedrinne [21] reported 5 data outcomes, and Wang et al. [24] reported 2 data outcomes. There was high heterogeneity ($I^2 = 95\%$, $p < 0.00001$); thus, the random effects model was used.
The pooled effect size showed significant differences in postoperative CK-MB levels (SMD = –2.30, 95% CI = –3.01 to –1.58, p < 0.0001) between the trimetazidine and control groups. In the ≤12 h postoperation subgroup analysis, all RCTs with the exception of that of Sher-i-Murtaza et al. [19], subgroups A and B, showed significant differences in postoperative CK-MB levels between the trimetazidine and control groups. In >12 h postoperation subgroup analysis, all RCTs with the exception of that of Sher-i-Murtaza et al. [19], subgroup C, showed significant differences in postoperative CK-MB levels between the trimetazidine and control groups.

**Meta-Analysis: Postoperative CK**

Figure 4 shows a Forest plot evaluating preoperative trimetazidine therapy by postoperative circulating CK levels. With respect to postoperative circulating CK levels, Sher-i-Murtaza et al. [19] reported 3 data outcomes. There was no heterogeneity detected (I² = 0%, p = 0.67); thus, the fixed effects model was used.

The pooled effect size showed no significant differences in postoperative CK-MB levels (SMD = 16.63, 95% CI = –63.49 to –96.74, p = 0.068) between the trimetazidine and control groups. In both the ≤12 and >12 h postoperation subgroup analyses, Sher-i-Murtaza et al. [19], subgroups A–C, showed no significant differences in postoperative CK-MB levels between the trimetazidine and control groups.

**Fig. 2.** Forest plot of RCTs evaluating preoperative trimetazidine and postoperative circulating CK levels. The squares and horizontal lines correspond to the SMDs and 95% CIs, respectively. The area of the squares reflects the study specific weight (inverse of the variance). The diamonds represent the pooled SMDs and 95% CIs.

---

**Meta-Analysis: Postoperative TnT**

Figure 5 shows a Forest plot evaluating preoperative trimetazidine therapy by postoperative circulating TnT levels. With respect to postoperative circulating TnT levels, Iskesen et al. [22] reported 3 data outcomes, Sher-i-Murtaza et al. [19] reported 3 data outcomes, and Tünerir et al. [20] reported 4 data outcomes. There was high heterogeneity (I² = 99%, p < 0.00001); thus, the random effects model was used.

The pooled effect size showed a significant difference in postoperative TnT levels (SMD = –1.42, 95% CI = –1.99 to –0.84, p < 0.00001) between the trimetazidine and control groups. In both the ≤12 and >12 h postoperation subgroup analyses, Iskesen et al. [22] and Tünerir et al. [20] showed significant differences between the trimetazidine and control groups.

**Meta-Analysis: Postoperative TnI**

Figure 6 shows a Forest plot evaluating preoperative trimetazidine therapy by postoperative circulating TnI levels. With respect to postoperative circulating TnI levels, Sher-i-Murtaza et al. [19] reported 3 data outcomes, and Tünerir et al. [20] reported 4 data outcomes. There was high heterogeneity (I² = 75%, p < 0.00001); thus, the random effects model was used.

The pooled effect size showed a significant difference in postoperative TnI levels (SMD = –0.89, 95% CI = –2.91 to 0.13, p < 0.00001) between the trimetazidine and control groups.

---
Fig. 3. Forest plot of RCTs evaluating preoperative trimetazidine and postoperative circulating CK-MB levels. The squares and horizontal lines correspond to the SMDs and 95% CIs, respectively. The area of the squares reflects the study specific weight (inverse of the variance). The diamonds represent the pooled SMDs and 95% CIs.

Fig. 4. Forest plot of RCTs evaluating preoperative trimetazidine and postoperative circulating CPK levels. The squares and horizontal lines correspond to the SMDs and 95% CIs, respectively. The area of the squares reflects the study specific weight (inverse of the variance). The diamonds represent the pooled SMDs and 95% CIs.
### Fig. 5. Forest plot of RCTs evaluating preoperative trimetazidine and postoperative circulating TnT levels. The squares and horizontal lines correspond to the SMDs and 95% CIs, respectively. The area of the squares reflects the study specific weight (inverse of the variance). The diamonds represent the pooled SMDs and 95% CIs.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Experimental Mean</th>
<th>Control Mean</th>
<th>Weight, %</th>
<th>SMD IV, Random, 95% CI</th>
<th>SMD IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Total</td>
<td>Mean</td>
<td>SD</td>
</tr>
<tr>
<td>≤12 h</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Xu [23], 2014, subgroup A</td>
<td>2.78</td>
<td>2.18</td>
<td>36</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wang [24], 2003, subgroup A</td>
<td>2.81</td>
<td>2.26</td>
<td>30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subtotal</td>
<td>66</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Heterogeneity: $\chi^2 = 0.00$, d.f. = 1 ($p < 0.99$), $I^2 = 0$
| Test for overall effect: $Z = 16.46$ ($p < 0.00001$) |
| >12 h             |      |    |       |      |    |       |                      |                      |
| Xu [23], 2014, subgroup B | 3.45 | 2.24 | 36   |     |    |       | 24.2                 | −10.11 [−12.11, −8.11] |
| Wang [24], 2003, subgroup B | 3.41 | 2.27 | 30   |     |    |       | 20.2                 | −10.34 [−12.53, −8.15] |
| Subtotal          | 66   |     |       |      |    |       |                      |                      |
| Heterogeneity: $\chi^2 = 0.02$, d.f. = 1 ($p = 0.88$), $I^2 = 0$
| Test for overall effect: $Z = 13.55$ ($p < 0.00001$) |
| Total             | 132  | 132 | 100   |      |    |       | −10.70 [−11.69, −9.72] |
| Heterogeneity: $\chi^2 = 0.78$, d.f. = 3 ($p = 0.85$), $I^2 = 0$
| Test for subgroup differences: $\chi^2 = 0.76$, d.f. = 1 ($p = 0.38$), $I^2 = 0$

### Fig. 6. Forest plot of RCTs evaluating preoperative trimetazidine and postoperative circulating TnI levels. The squares and horizontal lines correspond to the SMDs and 95% CIs, respectively. The area of the squares reflects the study specific weight (inverse of the variance). The diamonds represent the pooled SMDs and 95% CIs.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Experimental Mean</th>
<th>Control Mean</th>
<th>Weight, %</th>
<th>SMD IV, Random, 95% CI</th>
<th>SMD IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Total</td>
<td>Mean</td>
<td>SD</td>
</tr>
<tr>
<td>≤12 h</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Xu [23], 2014, subgroup A</td>
<td>2.87</td>
<td>2.18</td>
<td>36</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wang [24], 2003, subgroup A</td>
<td>2.81</td>
<td>2.26</td>
<td>30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subtotal</td>
<td>66</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Heterogeneity: $\chi^2 = 0.00$, d.f. = 1 ($p < 0.99$), $I^2 = 0$
| Test for overall effect: $Z = 16.46$ ($p < 0.00001$) |
| >12 h             |      |    |       |      |    |       |                      |                      |
| Xu [23], 2014, subgroup B | 3.45 | 2.24 | 36   |     |    |       | 24.2                 | −10.11 [−12.11, −8.11] |
| Wang [24], 2003, subgroup B | 3.41 | 2.27 | 30   |     |    |       | 20.2                 | −10.34 [−12.53, −8.15] |
| Subtotal          | 66   |     |       |      |    |       |                      |                      |
| Heterogeneity: $\chi^2 = 0.02$, d.f. = 1 ($p = 0.88$), $I^2 = 0$
| Test for overall effect: $Z = 13.55$ ($p < 0.00001$) |
| Total             | 132  | 132 | 100   |      |    |       | −10.70 [−11.69, −9.72] |
| Heterogeneity: $\chi^2 = 0.78$, d.f. = 3 ($p = 0.85$), $I^2 = 0$
| Test for subgroup differences: $\chi^2 = 0.76$, d.f. = 1 ($p = 0.38$), $I^2 = 0$
els, Xu et al. [23] reported 2 data outcomes, and Wang et al. [24] reported 2 data outcomes. There was no heterogeneity detected ($I^2 = 0\%$, $p = 0.85$); thus, the fixed effects model was used.

The pooled effect size showed a significant difference in postoperative TnT levels (SMD = −10.7, 95% CI = −11.69 to −9.72, $p < 0.00001$) between the trimetazidine and control groups. In both the $\leq 12$ and $>12$ h postoperation subgroup analyses, Xu et al. [23] and Wang et al. [24] showed significant differences between the trimetazidine and control groups.

**Bias Evaluation**

With respect to bias, the 2 TnI studies [23, 24] failed to blind participants, which may have been a source of bias in the TnI meta-analysis (fig. 7a). Accordingly, visual inspec-
tion of the funnel plots revealed slight asymmetry in these TnI studies as well (fig. 7), suggesting possible publication bias in the TnI meta-analysis. The remaining funnel plots did not appear to be grossly asymmetrical (fig. 7a–e).

**Discussion**

Here, we conducted a systematic review and meta-analysis of placebo-controlled RCTs to investigate the effectiveness of myocardial preservation of preoperative trimetazidine therapy in CABG patients by assessing the postoperative levels of several blood-based biochemical markers of myocardial injury. The pooled effect sizes showed significantly lower postoperative levels of CK, CK-MB, TnI and TnI in trimetazidine-treated CABG patients relative to control CABG patients. However, there were no significant differences in the postoperative CPK levels between the trimetazidine-treated CABG patients relative to control CABG patients. In sum, preoperative trimetazidine therapy appears to have a positive effect on myocardial preservation in CABG patients.

**Trimetazidine’s Cardioprotective Effects**

Trimetazidine is an anti-ischemic agent with demonstrated cardioprotective effects that works through several mechanisms. First, it inhibits long-chain mitochondrial 3-ketoacyl coenzyme A thiolase, which plays a key role in β-oxidation in cardiomyocytes [25]. This action switches cardiomyocyte metabolism from free fatty acid oxidation to glucose oxidation, which is more efficient at oxygen consumption and ATP production [25]. Second, through improving energy insufficiency, trimetazidine reduces sodium accumulation in cardiomyocyte cytoplasm, decreases reactive oxygen species formation and reduces neutrophil infiltration [25]. Third, trimetazidine reduces collagen accumulation, cardiac fibroblasts’ connective tissue growth factor expression, nicotinamide adenine dinucleotide phosphate oxidase levels and reactive oxygen species production [25]. Fourth, during reperfusion following an acute ischemic episode, trimetazidine also improves the sarcolemma’s mechanical resistance to edema-induced mechanical stress [25].

Clinically, trimetazidine has been shown to be effective in angina pectoris patients across several meta-analyses. The meta-analysis of Marzilli and Klein [26] of 12 trials consisting of 868 patients found that trimetazidine increased exercise duration to 1-mm segment depression on the exercise test and reduced anginal episodes. That of Ciapponi et al. [27] of 23 trials with 1,378 patients showed that trimetazidine reduced anginal attacks, nitroglycerine tablet consumption and improved exercise time to 1-mm segment depression on the exercise test. The network meta-analysis of Danchin et al. [7] of 218 trials with 19,028 patients showed trimetazidine improved exercise tolerance and weekly angina episodes; moreover, trimetazidine displayed similar anti-ischemic effects to dihydropyridines, long-acting nitrates, nicorandil and ranolazine. Most recently, the meta-analysis of Belsey et al. [28] also showed that trimetazidine used in conjunction with first-line β-blockers or calcium channel blockers showed improvement across several clinical outcomes.

In addition, trimetazidine has been shown to be effective in CHF patients across 3 meta-analyses. The meta-analysis of Gao et al. [29] of 17 RCTs with 955 CHF patients showed trimetazidine use was associated with increased exercise tolerance, New York Heart Association (NYHA) functional class reduction, improved left ventricular ejection fraction (LVEF), a reduced rate of cardiovascular events and hospitalizations, and reduction in overall mortality. The meta-analysis of Zhang et al. [10] of 16 RCTs with 884 patients demonstrated that trimetazidine use was associated with improved LVEF, increased exercise tolerance, reduced NYHA functional class, decreased left ventricular end-systolic volume and left ventricular end-diastolic volume, lowered B-type natriuretic peptide levels and a reduced rate of cardiovascular hospitalization; however, no reduction in overall mortality was observed [10]. Most recently, the meta-analysis of Zhou and Chen [9] of 19 RCTs with 994 CHF patients showed trimetazidine improved left ventricular ejection fraction and NYHA functional class while decreasing left ventricular end-systolic volume, left ventricular end-diastolic volume, hospitalization for cardiac causes, B-type natriuretic peptide and C-reactive protein; however, trimetazidine did not significantly affect exercise duration or all-cause mortality.

**Measuring Myocardial Preservation with Cardiac Markers**

Measuring myocardial preservation at the cellular level is a challenge. Here, in order to assess trimetazidine’s effectiveness at myocardial preservation in CABG patients, we analyzed the levels of 5 commonly used biochemical markers of myocardial injury (CK, CK-MB, TnI and TnI) as a proxy for myocardial preservation. In order to serve as a proxy for myocardial preservation, the ideal characteristics of a cardiac marker should be as follows: (i) the cardiac marker should be released into the circulation; (ii) the release of the cardiac marker into the circulation should occur in concert with and in propor-

---

**Preoperative Trimetazidine on Myocardial Preservation in CABG Patients**

Cardiology 2015;131:86–96
DOI: 10.1159/000375289
tion to the extent of myocardial cell death; (iii) the cardiac marker should possess a high myocardial concentration combined with a relatively low nonmyocardial concentration, which ensures a high myocardial specificity, and (iv) the cardiac marker should not associate or bind with other circulating factors in the bloodstream [30, 31]. As compared to CK-MB that is not unique to the heart and is found in skeletal muscle and the gastrointestinal tract and can form complexes with circulating immunoglobulins, TnI and TnT are unique to the cardiac myofibril’s contractile apparatus, have a higher percentage released into the bloodstream after cardiac injury, do not form immunoglobulin complexes, and display a superior persistence in the bloodstream owing to the slow release and slow degradation with a half-life of about 2 h, allowing for improved clinical detection after a cardiac event [31]. On this basis, the troponins (TnT, TnI) have been shown to be better predictors of post-CABG mortality than CK-MB; clinical studies comparing CK-MB with TnI and TnT have demonstrated that troponins are superior predictors of post-CABG mortality [32–34].

Here, we showed that both troponins (TnT, TnI) as well as CK-MB were all significantly reduced after trimetazidine therapy, which logically suggests that trimetazidine therapy improves post-CABG mortality. However, longer-term clinical trials on post-CABG patients that monitor all key cardiac biomarkers in addition to cardiovascular and all-cause mortality are required to validate this hypothesis.

Timing of Sample Collection

The timing of sample collection is also a key issue. After an acute myocardial injury, CK-MB and TnI take 2–8 h to increase above the upper reference limit, peaking between 14 and 36 h, and then remaining elevated 3–7 days after injury; TnT mimics the early release kinetics of TnI but can remain elevated for as long as 3 weeks [35]. However, the post-CABG release kinetics of these cardiac markers is complicated by other factors including preoperative myocardial injury and reperfusion injury, mediastinal blood retransfusion, graft failure, skeletal muscle injury (which disproportionally affects CK-MB levels), continuous extended release from degrading cardiac myofibrils (which disproportionally affects troponin levels), renal failure (which disproportionally affects troponin levels) and ischemic modification of molecules (which disproportionally affects TnI levels) [36]. Despite this physiological complexity, early cardiac marker release has been shown to predict length of stay in the hospital and adverse outcomes, but the majority of studies show that later release of cardiac markers (>12 h after cardiac event) are more clinically relevant [36].

Here, we divided the meta-analysis into early sample collection (≤12 h after operation) and late sample collection (>12 h after operation) in order to better assess the aforementioned effects of differential release kinetics. Comparing the pooled SMDs from the two timings on a marker-by-marker basis, we observed that CK (early –55.02 vs. late –385.77) and CK-MB (early –2.25 vs. late –2.45) showed more prominent SMDs in trimetazidine-treated CABG patients after 12 h while TnT (early –2.27 vs. late –0.79) and TnI (early –11.09 vs. late –10.21) showed more prominent SMDs in trimetazidine-treated CABG patients before 12 h. This data suggests that the creatine kinases (CK, CK-MB) and the troponins (TnT, TnI) display differing release kinetic profiles in trimetazidine-treated CABG patients. Further trials that measure these cardiac markers across multiple time points after CABG and correlate these measurements with hard clinical outcomes are needed to better analyze trimetazidine’s effects in CABG patients.

Study Limitations

Our systematic review has several limitations. First, study exclusion on the basis of language may have produced selection bias in the meta-analysis. For example, one large study including over 300 patients that was published in a Russian language journal by Lopatin and Dronova [37] was excluded on the basis of language and may have had a major impact on the current findings. Second, the number of included studies in each constituent meta-analysis was limited, and most of the included studies were relatively small in terms of sample size (i.e. with the exception of Sher-i-Murtaza et al. [19], all included studies had a sample size of under 100). Third, the included studies applied different protocols for preoperative trimetazidine therapy; the study of Vedrinne et al. [21] used a combination of oral and intravenous administration while the remaining studies solely used oral administration, and there were also differences in the duration of preoperative oral administration ranging from 1 day to 3 weeks prior to surgery (table 1). Fourth, the included studies cover a range of nearly two decades (1996–2014) in which the preoperative clinical management and surgical approaches to CABG patients have changed. Fifth, the studies used various types, manufacturers and generations of cardiac marker assays and employed various thresholds of significance. Sixth, there was a significantly high heterogeneity detected in the CK, CK-MB and TnT meta-analyses. Seventh, the 2 TnI studies [23, 24] failed to blind participants, which may have been
Table 1. Characteristics of included trials

<table>
<thead>
<tr>
<th>First author</th>
<th>Country</th>
<th>Trimetazidine group</th>
<th>Control group</th>
<th>Intervention</th>
<th>Follow-up</th>
<th>Reported outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sher-i-Murtaza [19], 2012</td>
<td>Pakistan</td>
<td>85</td>
<td>54.4±8.76</td>
<td>85</td>
<td>54.8±10.79</td>
<td>20 mg orally preoperatively (10 p.m. at night before day of surgery); 20 mg orally on the day of surgery</td>
</tr>
<tr>
<td>Tünerir [20], 1999</td>
<td>Turkey</td>
<td>15</td>
<td>57.1±2.2</td>
<td>15</td>
<td>58.4±1.2</td>
<td>60 mg q.d. for 3 weeks preoperatively</td>
</tr>
<tr>
<td>Vedrinne [21], 1996</td>
<td>France</td>
<td>20</td>
<td>61.0±2.0</td>
<td>20</td>
<td>62.0±2.0</td>
<td>20 mg orally t.i.d. for ≥15 days preoperatively; 40 mg as a bolus before skin incision; 2.5 mg/h up to the sixth postoperative hour</td>
</tr>
<tr>
<td>Iskesen [22], 2009</td>
<td>Turkey</td>
<td>15</td>
<td>57.5±2.6</td>
<td>15</td>
<td>60.2±2.1</td>
<td>20 mg orally t.i.d. for 2 weeks preoperatively; 60 mg on the day of surgery</td>
</tr>
<tr>
<td>Xu [23], 2014</td>
<td>China</td>
<td>36</td>
<td>60.4±10.5</td>
<td>36</td>
<td>62.3±11.3</td>
<td>20 mg orally t.i.d. for 1 week preoperatively; 60 mg on the day of surgery</td>
</tr>
<tr>
<td>Wang [24], 2003</td>
<td>China</td>
<td>30</td>
<td>59.5±11.4</td>
<td>30</td>
<td>62.1±9.6</td>
<td>20 mg orally t.i.d. for 3 weeks preoperatively</td>
</tr>
</tbody>
</table>

Conclusions

This systematic review and meta-analysis of 6 placebo-controlled RCTs investigated the effectiveness of preoperative trimetazidine therapy on myocardial preservation in CABG patients by assessing the postoperative levels of several blood-based biochemical markers of myocardial injury. Significantly lower postoperative levels of CK, CK-MB, TnT and TnI were found in the trimetazidine-treated CABG patients relative to control CABG patients. In sum, preoperative trimetazidine therapy appears to have a positive effect on myocardial preservation in CABG patients.

Acknowledgments

This study was supported by the Chongqing Science and Technology Commission (grant No. cstc2011ggcx0003).

Conflicts of Interest

None.

References


